• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

The elucidation and control of mechanisms underlying inhibition of myocardial conditioning with risk factors in coronary disease

Research Project

Project/Area Number 24791600
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Anesthesiology/Resuscitation studies
Research InstitutionNagasaki University

Principal Investigator

HIGASHIJIMA Ushio  長崎大学, 大学病院(医学系), 助教 (20380909)

Project Period (FY) 2012-04-01 – 2015-03-31
Project Status Completed (Fiscal Year 2014)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords強心薬 / 心筋梗塞サイズ縮小 / ポストコンディショニング / 心筋梗塞サイズ / 心筋保護効果 / レボシメンダン / ミルリノン / プロポフォール / ミトコンドリアATP感受性カリウムチャネル / 薬理学的ポストコンディショニング / プレコンディショニング
Outline of Final Research Achievements

We investigated the mechanism of cardioprotection associated with two inotropics, milrinone:MIL, a phosphodiesterase type 3 inhibitor, and levosimendan:LEV, a calcium sensitizer. A selective cyclooxygenase-2 inhibitor abolished LEV-induced cardioprotection(postconditioning). Now we try to clarify the activation of cyclooxygenase-2 protein in the cardioprotection with Westernblotting. Preischemic administration of MIL or LEV have showed tendency to decrease the myocardial infarct size, but not significant. Propofol(the Group of propofol+MIL or propofol+LEV) also have showed tendency to increase the myocardial infarct size compared with the Group of MIL or LEV(preischemic administration: i.e. preconditioning), but not significant.

Report

(4 results)
  • 2014 Annual Research Report   Final Research Report ( PDF )
  • 2013 Research-status Report
  • 2012 Research-status Report

URL: 

Published: 2013-05-31   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi